Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study

Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COV...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese Journal of Infectious Diseases 2022/09/30, Vol.75(5), pp.484-489
Hauptverfasser:	Soma, Tomomi, Fujii, Kentaro, Yoshifuji, Ayumi, Maruki, Taketomo, Itoh, Kazuto, Taniyama, Daisuke, Kikuchi, Takahide, Hasegawa, Naoki, Nakamura, Morio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral agents coronavirus disease Coronaviruses COVID-19 Health services Hyperkalemia Intravenous administration Intravenous infusion Laboratories nafamostat mesylate Patients Risk groups SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 single-center study Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!